The therapeutic index of antineoplastic agents is generally low, therefore, errors in administration can cause severe, life-threatening toxicity. The publication of cases of overdoses may provide useful information on the causes of the mistakes, on drug-induced toxic effects, and on salvage therapy. We report a case of vinblastine overdose in a child affected by Langerhans' cell histiocytosis, Hand-Schüller-Christian syndrome according with the previous classification of histiocytosis X. To our knowledge this is the highest dose of vinblastine ever administered. The child was given salvage therapy with steroids and citrovorum factor. Major side effects were neurologic toxicity (seizures, coma) and marrow aplasia, which improved and gradually resolved beginning day 12.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3109/08880019109033444 | DOI Listing |
Clin Exp Metastasis
January 2025
Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Oligorecurrent prostate cancer (PCa) can be treated with metastasis-directed therapy (MDT), which may be performed using radioguided surgery (RGS) as an experimental approach. These procedures have shown promising outcomes, largely due to the high lesion detection rate of positron emission tomography/computed tomography (PET/CT). We present a case series of patients who underwent RGS following robot-assisted radical prostatectomy (RARP).
View Article and Find Full Text PDFJ Neurol Surg B Skull Base
February 2025
Department of Otorhinolaryngology, Tan Tock Seng Hospital, Singapore.
Primary extracranial meningiomas (PEMs) of the sinonasal tract with no intracranial extension are rare. Our study presents the largest systematic review to date, providing a comprehensive overview and comparison of the characteristics, treatment, and prognosis of PEMs, with comparison to primary intracranial meningiomas (PIMs). A systematic review was conducted according to the PRISMA guidelines on PubMed, Embase, and Google Scholar up to November 1, 2022.
View Article and Find Full Text PDFBackground: Although revascularization is first-line therapy for chronic limb-threatening ischemia (CLTI), there are no established treatments for patients in whom revascularization is not (or is a poor) option, including CLTI that has responded poorly to revascularization. This study verified the efficacy of the Rheocarna, a novel apheresis device, for no-option CLTI or poor-response CLTI after revascularization.
Methods And Results: This multicenter retrospective observational study analyzed 221 patients (221 limbs) with no- or poor-option CLTI (mean [±SD] age 71±10 years; males, 70.
BJUI Compass
January 2025
Department of Urology, Institute of Urologic Oncology UCLA Los Angeles California USA.
Objectives: The aim of this study is to evaluate new software (Unfold AI) in the estimation of prostate tumour volume (TV) and prediction of focal therapy outcomes.
Subjects/patients And Methods: Subjects were 204 men with prostate cancer (PCa) of grade groups 2-4 (GG ≥ 2), who were enrolled in a trial of partial gland cryoablation (PGA) at UCLA from 2017 to 2022. Magnetic resonance imaging (MRI)-guided biopsy (MRGB) was performed at diagnosis and at 6 and 18 months following PGA.
Int Angiol
December 2024
Department of Vascular Surgery, Shebin Elkoom Teaching Hospital, Shebin Elkoom, Egypt.
Background: The peroneal artery is known to give branches to the anterior and posterior tibial arteries. Scattered reports in the literature over the last decade failed to provide solid evidence as to the optimum strategy for below-knee targeted revascularization in limited-option patients with critical limb-treating ischemia (CLTI). We sought to determine the benefit of performing single peroneal tibial artery angioplasty revascularization compared with single non-peroneal angiosome-targeted tibial artery angioplasty revascularization for patients presented with CLTI.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!